|Neurotoxicity Assays Using iPSC-Derived Neurons and High Content Imaging|
Oksana Sirenko, Susan DeLaura, Lucas Chase, Jayne Hesley and Evan F. Cromwell
Neurotoxicity can cause temporary or permanent damage of brain or peripheral nervous system and has been found to be a major cause of neurodegenerative diseases such as Alzheimer’s or Parkinson’s. Accordingly, there is a great interest in developing more predictive, disease relevant cell-based models and efficient screening tools for assessing the neurotoxicity of chemical compounds, drug candidates and environmental agents.
|SpectraMax® Microplate Readers: A complete solution for Transcreener® assays|
Cathleen Salono, Caroline Cardonnel, Kasia Proctor and Cathy Olsen
Transcreener® ADP2 Assays are homogenous assays with fluorescent readouts that enable the detection and screening of established drug targets including protein and lipid kinases, as well as emerging targets such as carbohydrate kinases, triphosphatases, heat shock proteins and other ATPases.
|Live Cell Beating Assay Using Human iPSC-derived Cardiomyocytes for Evaluation of Drug Efficacy and Toxicity|
Oksana Sirenko, Carole Crittenden, Blake Anson, Jayne Hesley, Yen-Wen Chen, Nick Callamaras and Evan F. Cromwell
A large percentage of new drugs fail in clinical studies due to cardiac toxicity. Development of highly predictive in vitro assays suitable for screening, safety assessment or other environments is therefore extremely important for drug development. Human cardiomyocytes derived from stem cell sources can greatly accelerate the discovery of cardiac drugs and improve drug safety by offering more clinically relevant cell-based models than those presently available.
|Quantification of cytokines on the SpectraMax® Paradigm® Multi-Mode Microplate Detection Platform using Alpha Technology|
Caroline Cardonnel, Cathleen Salomo, Michael Katzlinger, Yvonne Fitzgerald, Cathy Olsen and Harald Hundsberger
Inflammation is accompanied by increased endothelial chemokine production and adhesion molecule expression, which may result in an extensive neutrophil infiltration. As such, the search for novel anti-inflammatory substances able to downregulate these parameters, as well as tissue damage, holds therapeutic promise.
|Is it possible to quantify and rank the quality of several lists of significant genes found with gene expression profiling by different methods?|
Joachim R. Grün (1), Andreas Grützkau (1), Biljana Smiljanovic (1), Thomas Häupl (2), Gerd-Rüdiger Burmester (2), Andreas Radbruch (1)
High Performance Chip Data Analysis (HPCDA) improves expression profiling of Affymetrix chips via Bioretis database: you can easily use the default parameters and are sure to get the optimum of true positive results, independant of number of significant genes in your dataset. Gene List Significance Index (GLSI) quantifies quality of gene lists. With GLSI its easily judged which normalization/analyzing method gives better results. HPCDA score ranks by relevance.
|Target length effect on sensitivity and specificity of oligonucleotide microarrays: Advantages of a modified PCR based labelling method over the dendrimer technology.|
Abdullah Gibriel1*, Walter Kolch2 and Andrew Pitt1,3
Several methods have been developed for target labelling to enable DNA microarray quantification without taking careful consideration for target length effect. This report highlights the importance of choosing the optimum target length that would ensure specificity without compromising sensitivity of the assay. It also shows the advantages of using the modified PCR method over other methods in generating labelled amplicons of the desired lengths to maximize hybridization efficiency.
|Electrochemical Microfluidic Biosensor for E.coli Detection|
Mohammadali Safavieh, Minhaz Uddin Ahmed, and Mohammed Zourob
Microfluidic electrochemical biosensor based on Loop-mediated Isothermal Amplification (LAMP) was developed for detection and quantification of E.coli. The electrochemical detection was achieved using Hoechst 33258 redox molecule and linear sweep voltametry (LSV). Here, we detect and quantify 48 CFU/ml of bacteria in 35 min in LB media and urine samples. This microfluidic chip has great potential to be used as a point of care diagnostic (POC) device for clinical application.
|Identification of novel autoantigensin patients with liver autoimmune diseases by Protein MicroArray|
C. Zingaretti1, M. Arigò1, A. Cardaci1, A. Sinisi1, L. Muratori3, P. Colombatto4, F. Bonino2, P. Invernizzi5, , A.L. Zignego6 MC. Crosti1, M. Moro1, J. Geginat1, Pagani M.1, R. De Francesco1, S. Abrignani1. & M. Bombaci1
The characterization of autoimmune disease-specific biomarkers are of primary importance for the development of diagnostic tools and the comprehension of pathogenetic mechanisms leading to autoimmunity. To this aim a protein microarray was employed to analyze serum samples from patients with autoimmune hepatitis (e.g. AIH & PBC) and of healthy as controls. A panel of autoantigens able to discriminate among the groups of patients was identified for potential use as biomarkers.
|GALAS Modeling Methodology Applications In The Prediction Of Drug Metabolism Related Properties|
Remigijus Didziapetris, Justas Dapkunas, Andrius Sazonovas and Pranas Japertas
Analytical identification of metabolites for a drug candidate is usually a time consuming and low-throughput task and is performed only at the later phases of drug development. Therefore the possibility to predict possible sites of human liver microsomal (HLM) metabolism using in silico techniques would be a very attractive feature for any medicinal chemist.